The hitch for next-up glucagon-like peptide-1 inhibitor Bydureon, better known as Amylin Pharmaceuticals Inc.'s Byetta LAR, got Wall Street talking - again, more - last week about diabetes and obesity. Woebegone Mannkind Corp. stumbled, too, with its Exubera-haunted inhaled insulin Afrezza. But another bit of happier (albeit early stage) news in the space slipped out quietly, when NGM Biopharmaceuticals Inc. disclosed the first tranche of financing in a $51 million Series B round. Read More
